Positive Phase 3 Trial
Celldex Therapeutics reports positive Phase 3 trial results for barzolvolimab in treating chronic spontaneous urticaria.
Anonymous
Key Points
1
The two trials randomized 1,939 adults to barzolvolimab 150 mg every four weeks, 300 mg every eight weeks, or placebo for 24 weeks; placebo participants were then re-randomized to active treatment.
2
At Week 12, mean UAS7 reductions were approximately 20 points with barzolvolimab versus about 11 points with placebo, a difference that was highly statistically significant (p<0.00001).
3
Complete-response rates, defined as UAS7=0, reached 42%–46% with barzolvolimab at Week 12 compared with 9%–13% for placebo, before rising further by Week 24.
4
The studies found statistically higher rates of complete angioedema resolution, measured by AAS7=0, among barzolvolimab-treated patients than among those receiving placebo at Week 12.
5
Celldex is developing barzolvolimab as an antibody therapy targeting mast cells, which play a role in allergic and inflammatory responses.
Celldex Therapeutics reported positive Phase 3 trial results for barzolvolimab, a new treatment for chronic spontaneous urticaria (CSU), a serious allergic skin condition. RTTNews reported that Yahoo Finance showed both EMBARQ-CSU1 and EMBARQ-CSU2 trials met their primary endpoints and all key secondary endpoints. At Week 12, patients taking barzolvolimab had urticaria activity scores drop by approximately 20 points, versus 11 points for placebo — a highly statistically significant difference (p<0.00001).
Despite the clinical success, Celldex shares fell sharply in premarket trading and later settled near $37.89. RTTNews reported that shares dropped around 17% after the announcement, suggesting investors questioned the drug's commercial potential or timeline. The company plans to file its Biologics License Application with the FDA in 2027.
Barzolvolimab Delivered Dramatic Improvements in Complete Responses
Complete-response rates, where urticaria activity completely stopped, reached 42%–46% with barzolvolimab at Week 12 compared with just 9%–13% for placebo, according to Clinical Trials Arena. These improvements continued through Week 24. Barzolvolimab also showed higher rates of complete angioedema resolution — swelling in deeper skin layers — than placebo at Week 12, addressing a painful symptom that standard antihistamines often fail to control.
How Barzolvolimab Works and Who It Targets
Barzolvolimab is an antibody therapy that targets mast cells, immune cells that trigger allergic and inflammatory responses in the body, according to The Pharma Letter. The drug was tested in 1,939 adults with CSU who had not adequately responded to H1 antihistamines, the standard first-line treatment. The trials included a particularly important subgroup: patients who had also failed omalizumab, a biologic drug reserved for severe cases.
Treatment was Well-Tolerated With No Safety Surprises
Barzolvolimab showed rapid and sustained efficacy over 24 weeks with no new safety signals reported, GRAFA noted. Patients received either 150 mg every four weeks or 300 mg every eight weeks. The trials will continue through 52 weeks to gather longer-term safety and durability data before the FDA application in 2027.
The Market's Skepticism Despite Clinical Success
Positive clinical data does not always translate to stock gains. Investors often worry about manufacturing scale, pricing power, reimbursement barriers, and competitive threats. A 17% one-day drop despite meeting all trial endpoints suggests the market may doubt barzolvolimab's commercial viability or question whether the benefit justifies its eventual cost to patients and healthcare systems.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
38
Reach
53
Topics
A
AnonymousAuthor
